Nanotechnology-based drug delivery systems for melanoma antitumoral therapy: A review

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Rigon, Roberta Balansin ^a   Oyafuso, Márcia Helena ^a   Fujimura, Andressa Terumi ^a   Gonçalez, Maíra Lima ^a   Do Prado, Alice Haddad ^a   Gremião, Maria Palmira Daflon ^a   Chorilli, Marlus ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETULIN; CAMPTOTHECIN; CYCLODEXTRIN; DOCETAXEL; INTERLEUKIN 2; LIPID NANOPARTICLE; LIPOSOME; NANOCAPSULE; NANOPARTICLE; NANOSPHERE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CLINICAL STUDY; DRUG DELIVERY SYSTEM; HUMAN; HYDROGEL; LIQUID CRYSTAL; MELANOMA; MICELLE; NANOTECHNOLOGY; NONHUMAN; PHOTODYNAMIC THERAPY; REVIEW; SLOW DRUG RELEASE; CHEMISTRY; PATHOLOGY;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MELANOMA; NANOPARTICLES; NANOTECHNOLOGY;

EID: 84930630910     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/841817     Document Type: Review

References (282)

1. H. J. Cohen, E. Cox, K. Manton, and M. Woodbury, "Malignant melanoma in the elderly", Journal of Clinical Oncology, vol. 5, no. 1, pp. 100-106, 1987.
2. P. E. Le Boit, Pathology & Genetics: Skin Tumours, edited by: World Health Organization, IARC Press, Lyon, France, 2006.
3. R. N. Saladi and A. N. Persaud, "The causes of skin cancer: a comprehensive review", Drugs of Today, vol. 41, no. 1, pp. 37-53, 2005.
4. E. De Vries, F. I. Bray, J. W. W. Coebergh, and D. M. Parkin, "Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia", International Journal of Cancer, vol. 107, no. 1, pp. 119-126, 2003.
5. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, "Estimates of worldwide burden of cancer in 2008: GLOBOCAN2008", International Journal of Cancer, vol. 127, no. 12, pp. 2893-2917, 2010.
6. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics", CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69-90, 2011.
7. R. Colombari, F. Bonetti, G. Zamboni et al., "Distribution of melanoma specific antibody (HMB-45) in benign and malignant melanocytic tumours. An immunohistochemical study on paraffin sections", Virchows Archiv A, vol. 413, no. 1, pp. 17-24, 1988.
8. K. Blessing, D. S. A. Sanders, and J. J. H. Grant, "Comparison of immunohistochemical staining of the novel antibodymelan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants", Histopathology, vol. 32, no. 2, pp. 139-146, 1998.
9. T. Gambichler, P. Regeniter, F. G. Bechara et al., "Characterization of benign and malignant melanocytic skin lesions using optical coherence tomography in vivo", Journal of the American Academy of Dermatology, vol. 57, no. 4, pp. 629-637, 2007.
10. R. Harson and C. Grose, "Egress of varicella-zoster virus from the melanoma cell: a tropism for the melanocyte", Journal of Virology, vol. 69, no. 8, pp. 4994-5010, 1995.
11. A. Ingraffea, "Melanoma", Facial Plastic Surgery Clinics of North America, vol. 21, no. 1, pp. 33-42, 2013.
12. J. Y. Lin and D. E. Fisher, "Melanocyte biology and skin pigmentation", Nature, vol. 445, no. 7130, pp. 843-850, 2007.
13. Y. Yamaguchi and V. J. Hearing, "Physiological factors that regulate skin pigmentation", BioFactors, vol. 35, no. 2, pp. 193-199, 2009.
14. S. L. Winsey, N. A. Haldar, H. P. Marsh et al., "A variant within the DNA repair geneXRCC3 is associated with the development of melanoma skin cancer", Cancer Research, vol. 60, no. 20, pp. 5612-5616, 2000.
15. D. B. McKenna, V. R. Doherty, K. M. Mclaren, and J. A. A. Hunter, "Malignant melanoma and lymphoproliferative malignancy: is there a shared aetiology?" British Journal of Dermatology, vol. 143, no. 1, pp. 171-173, 2000.
16. V. Bataille, "Genetic epidemiology of melanoma", European Journal of Cancer, vol. 39, no. 10, pp. 1341-1347, 2003.
17. M. S. Brose, P. Volpe, M. Feldman et al., "BRAF and RAS mutations in human lung cancer and melanoma", Cancer Research, vol. 62, no. 23, pp. 6997-7000, 2002.
18. K. Omholt, S. Karsberg, A. Platz, L. Kanter, U. Ringborg, and J. Hansson, "Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneousmelanomas: mutations occur early and persist throughout tumor progression", Clinical Cancer Research, vol. 8, no. 11, pp. 3468-3474, 2002.
19. M. A. Tucker and A. M. Goldstein, "Melanoma etiology: where are we?" Oncogene, vol. 22, no. 20, pp. 3042-3052, 2003.
20. M.-F. Demierre and V. K. Sondak, "Cutaneous melanoma: pathogenesis and rationale for chemoprevention", Critical Reviews in Oncology/Hematology, vol. 53, no. 3, pp. 225-239, 2005.
21. K. Colston, M. J. Colston, and D. Feldman, "1, 25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture", Endocrinology, vol. 108, no. 3, pp. 1083-1086, 1981.
22. D. E. Godar, R. J. Landry, and A. D. Lucas, "Increased UVA exposures and decreased cutaneous Vitamin D3 levels may be responsible for the increasing incidence of melanoma", Medical Hypotheses, vol. 72, no. 4, pp. 434-443, 2009.
23. S. V. Madhunapantula and G. P. Robertson, "Chemoprevention of Melanoma", Advances in Pharmacology, vol. 65, pp. 361-398, 2012.
24. D. C. Whiteman, P. Watt, D. M. Purdie, M. C. Hughes, N. K. Hayward, and A. C. Green, "Melanocytic nevi, solar keratoses, and divergent pathways to cutaneousmelanoma", Journal of the National Cancer Institute, vol. 95, no. 11, pp. 806-812, 2003.
25. M. Megahed, M. Schön, D. Selimovic, and M. P. Schön, "Reliability of diagnosis of melanoma in situ", The Lancet, vol. 359, no. 9321, pp. 1921-1922, 2002.
26. G. Massi and P. E. Leboit, "Melanoma in situ", in Histological Diagnosis of Nevi and Melanoma, pp. 403-412, Springer, 2004.
27. W. H. Clark Jr. and M. C. Mihm Jr., "Lentigo maligna and lentigo-malignamelanoma", American Journal of Pathology, vol. 55, no. 1, pp. 39-67, 1969.
28. V. Cardile, G. Malaponte, C. Loreto et al., "Raf kinase inhibitor protein (RKIP) and phospho-RKIP expression in melanomas", Acta Histochemica, vol. 115, no. 8, pp. 795-802, 2013.
29. R. T. Prehn, "The paradoxical association of regression with a poor prognosis in melanoma contrasted with a good prognosis in keratoacanthoma", Cancer Research, vol. 56, no. 5, pp. 937-940, 1996.
30. S. M. Swetter, P. M. Ecker, D. L. Johnson, and J. D. Harvell, "Primary dermal melanoma: a distinct subtype of melanoma", Archives of Dermatology, vol. 140, no. 1, pp. 99-103, 2004.
31. K. Hoek, D. L. Rimm, K. R. Williams et al., "Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas", Cancer Research, vol. 64, no. 15, pp. 5270-5282, 2004.
32. D. Grossman and D. C. Altieri, "Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets", Cancer and Metastasis Reviews, vol. 20, no. 1-2, pp. 3-11, 2001.
33. M. Karin and A. Lin, "NF-κB at the crossroads of life and death", Nature Immunology, vol. 3, no. 3, pp. 221-227, 2002.
34. L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani, "Toward a molecular classification of melanoma", Journal of Clinical Oncology, vol. 25, no. 12, pp. 1606-1620, 2007.
35. L. M. Cohen, "Lentigo maligna and lentigomaligna melanoma", Journal of the American Academy of Dermatology, vol. 33, no. 6, pp. 923-939, 1995.
36. S. Menzies, "Superficial spreading melanoma", in An Atlas of Dermoscopy, J. M. Ashfaq, A. Marghoob, and R. Marghoob, Eds., pp. 203-209, CRC Press, 2004.
37. A. E. Chang, L. H. Karnell, and H. R. Menck, "The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84, 836 cases from the past decade", Cancer, vol. 83, no. 8, pp. 1664-1678, 1998.
38. E. T. Krementz, R. J. Reed, and W. P. Coleman III, "Acral lentiginous melanoma. A clinicopathologic entity", Annals of Surgery, vol. 195, no. 5, pp. 632-645, 1982.
39. R. A. Scolyer, G. V. Long, and J. F. Thompson, "Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care", Molecular Oncology, vol. 5, no. 2, pp. 124-136, 2011.
40. N. J. Crowley and H. F. Seigler, "Late recurrence of malignant melanoma: analysis of 168 patients", Annals of Surgery, vol. 212, no. 2, pp. 173-177, 1990.
41. M.-H. Schmid-Wendtner, J. Baumert, M. Schmidt et al., "Late metastases of cutaneous melanoma: an analysis of 31 patients", Journal of the American Academy of Dermatology, vol. 43, no. 4, pp. 605-609, 2000.
42. A. J. Sober and J. M. Burstein, "Precursors to skin cancer", Cancer, vol. 75, no. 2, supplement, pp. 645-650, 1995.
43. K. Hoffmann, J. Jung, S. El Gammal, and P. Altmeyer, "Malignant melanoma in 20-MHz B scan sonography", Dermatology, vol. 185, no. 1, pp. 49-55, 1992.
44. T. S. Wang, T. M. Johnson, P. N. Cascade, B. G. Redman, V. K. Sondak, and J. L. Schwartz, "Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma", Journal of the American Academy of Dermatology, vol. 51, no. 3, pp. 399-405, 2004.
45. C. M. Balch, A. C. Buzaid, S.-J. Soong et al., "Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma", Journal of Clinical Oncology, vol. 19, no. 16, pp. 3635-3648, 2001.
46. S. B. Revin and S. A. John, "Electrochemical marker for metastatic malignant melanoma based on the determination of l-dopa/l-tyrosine ratio", Sensors and Actuators B: Chemical, vol. 188, pp. 1026-1032, 2013.
47. D. S. Tyler, M. Onaitis, A. Kherani et al., "Positron emission tomography scanning inmalignant melanoma: clinical utility in patients with Stage III disease", Cancer, vol. 89, no. 5, pp. 1019-1025, 2000.
48. 3-targeted magnetic resonance imaging", Nature Medicine, vol. 4, no. 5, pp. 623-626, 1998.
49. D. Rinne, R. P. Baum, G. Hör, and R. Kaufmann, "Primary staging and follow-up of high risk melanoma patients with wholebody 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients", Cancer, vol. 82, no. 9, pp. 1664-1671, 1998.
50. M. González Cao, J. M. Auge, R. Molina et al., "Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma", Anticancer Research, vol. 27, no. 1B, pp. 595-599, 2007.
51. L. L. Yu, T. J. Flotte, K. K. Tanabe et al., "Detection of microscopic melanoma metastases in sentinel lymph nodes", Cancer, vol. 86, no. 4, pp. 617-627, 1999.
52. M. B. Sporn, N. M. Dunlop, D. L. Newton, and J. M. Smith, "Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)", Federation Proceedings, vol. 35, no. 6, pp. 1332-1338, 1976.
53. F. L. Meyskens Jr., P. J. Farmer, and H. Anton-Culver, "Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk", Clinical Cancer Research, vol. 10, no. 8, pp. 2581-2583, 2004.
54. A. V. Anstey, "Systemic photoprotection with α-tocopherol (vitamin E) and β-carotene", Clinical and Experimental Dermatology, vol. 27, no. 3, pp. 170-176, 2002.
55. W. Stahl and H. Sies, "Carotenoids and protection against solar UV radiation", Skin Pharmacology and Applied Skin Physiology, vol. 15, no. 5, pp. 291-296, 2002.
56. H. Tsao, M. Feldman, J. E. Fullerton, A. J. Sober, D. Rosenthal, and W. Goggins, "Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival", Archives of Dermatology, vol. 140, no. 1, pp. 67-70, 2004.
57. E. Erdei and S. M. Torres, "Anewunderstanding in the epidemiology of melanoma", Expert Review of Anticancer Therapy, vol. 10, no. 11, pp. 1811-1823, 2010.
58. D. Kavanagh, A. D. K. Hill, B. Djikstra, R. Kennelly, E. M. W. McDermott, and N. J. O'Higgins, "Adjuvant therapies in the treatment of stage II and IIImalignantmelanoma", Surgeon, vol. 3, no. 4, pp. 245-256, 2005.
59. S. Schreiber, E. Kämpgen, E. Wagner et al., "Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study", Human Gene Therapy, vol. 10, no. 6, pp. 983-993, 1999.
60. R. W. Dubois, S. M. Swetter, M. Atkins et al., "Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma", Archives of Dermatology, vol. 137, no. 9, pp. 1217-1224, 2001.
61. H. Tsao, M. B. Atkins, and A. J. Sober, "Management of cutaneous melanoma", The New England Journal of Medicine, vol. 351, no. 10, pp. 998-1012, 2004.
62. S. Hu, Y. Parmet, G. Allen et al., "Disparity in melanoma: a trend analysis of melanoma incidence and stage at diagnosis among whites, Hispanics, and blacks in Florida", Archives of Dermatology, vol. 145, no. 12, pp. 1369-1374, 2009.
63. V. K. Sondak and G. T. Gibney, "Indications and options for systemic therapy in melanoma", Surgical Clinics of North America, vol. 94, no. 5, pp. 1049-1058, 2014.
64. S. Stadler, K. Weina, C. Gebhardt, and J. Utikal, "New therapeutic options for advanced non-resectable malignant melanoma", Advances in Medical Sciences, vol. 60, no. 1, pp. 83-88, 2015.
65. A. Ribas, A. Hauschild, R. Kefford et al., "Phase III, openlabel, randomized, comparative study of tremelimumab (CP-675, 206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma", Journal of Clinical Oncology, vol. 26, no. 15, supplement, 2008.
66. M. A. Postow, J. Chesney, A. C. Pavlick et al., "Nivolumab and ipilimumab versus ipilimumab in untreated melanoma", The New England Journal of Medicine, 2015.
67. S. Bagcchi, "Pembrolizumab for treatment of refractory melanoma", The Lancet Oncology, vol. 15, no. 10, Article e419, 2014.
68. T. K. Burki, "Variation in prostate cancer management", The Lancet Oncology, vol. 15, no. 10, p. e419, 2014.
69. B. V. Bonifácio, P. B. Da Silva, M. Aparecido Dos Santos Ramos, K. Maria Silveira Negri, T. Maria Bauab, and M. Chorilli, "Nanotechnology-based drug delivery systems and herbal medicines: a review", International Journal of Nanomedicine, vol. 9, no. 1, pp. 1-15, 2014.
70. R. M. Mainardes, M. C. Cocenza Urban, P. O. Cinto, M. V. Chaud, R. C. Evangelista, and M. P. Daflon Gremião, "Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery", Current Drug Delivery, vol. 3, no. 3, pp. 275-285, 2006.
71. R. N. Saha, S. Vasanthakumar, G. Bende, and M. Snehalatha, "Nanoparticulate drug delivery systems for cancer chemotherapy", Molecular Membrane Biology, vol. 27, no. 7, pp. 215-231, 2010.
72. A. E. Grill, N. W. Johnston, T. Sadhukha, and J. Panyam, "A review of select recent patents on novel nanocarriers", Recent Patents on Drug Delivery and Formulation, vol. 3, no. 2, pp. 137-142, 2009.
73. J. Venugopal, M. P. Prabhakaran, S. Low et al., "Continuous nanostructures for the controlled release of drugs", Current Pharmaceutical Design, vol. 15, no. 15, pp. 1799-1808, 2009.
74. V. P. Torchilin, "Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery", Nature Reviews Drug Discovery, vol. 13, no. 11, pp. 813-827, 2014.
75. A. Kumar, A. Srivastava, I. Y. Galaev, and B. Mattiasson, "Smart polymers: physical forms and bioengineering applications", Progress in Polymer Science, vol. 32, no. 10, pp. 1205-1237, 2007.
76. M. P. Patel, S. T. Churchman, A. T. Cruchley, M. Braden, and D. M. Williams, "Delivery of macromolecules across oral mucosa from polymeric hydrogels is enhanced by electrophoresis (iontophoresis)", Dental Materials, vol. 29, no. 11, pp. e299-e307, 2013.
77. S. Thomas, R. Shanks, and C. Sarathchandran, Nanostructured Polymer Blends, edited by: W. Andrew, Elsevier, Oxford, UK, 1st edition, 2013.
78. T. R. Hoare and D. S. Kohane, "Hydrogels in drug delivery: progress and challenges", Polymer, vol. 49, no. 8, pp. 1993-2007, 2008.
79. M. Casolaro, D. B. Barbara, and M. Emilia, "Hydrogel containing l-valine residues as a platform for cisplatin chemotherapy", Colloids and Surfaces B: Biointerfaces, vol. 88, no. 1, pp. 389-395, 2011.
80. J. L. Drury and D. J. Mooney, "Hydrogels for tissue engineering: scaffold design variables and applications", Biomaterials, vol. 24, no. 24, pp. 4337-4351, 2003.
81. S. W. Kim, Y. H. Bae, and T. Okano, "Hydrogels: swelling, drug loading, and release", Pharmaceutical Research, vol. 9, no. 3, pp. 283-290, 1992.
82. R. Vasita and D. S. Katti, "Nanofibers and their applications in tissue engineering", International Journal of Nanomedicine, vol. 1, no. 1, pp. 15-30, 2006.
83. N. A. Peppas, P. Bures, W. Leobandung, and H. Ichikawa, "Hydrogels in pharmaceutical formulations", European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 27-46, 2000.
84. D. J. Murphy, M. G. Sankalia, R. G. Loughlin, R. F. Donnelly, M. G. Jenkins, and P. A. Mccarron, "Physical characterisation and component release of poly (vinyl alcohol)-tetrahydroxyborate hydrogels and their applicability as potential topical drug delivery systems", International Journal of Pharmaceutics, vol. 423, no. 2, pp. 326-334, 2012.
85. N. Bhattarai, J. Gunn, and M. Zhang, "Chitosan-based hydrogels for controlled, localized drug delivery", Advanced Drug Delivery Reviews, vol. 62, no. 1, pp. 83-99, 2010.
86. Y. Gao, J. Xie, H. Chen et al., "Nanotechnology-based intelligent drug design for cancer metastasis treatment", Biotechnology Advances, vol. 32, no. 4, pp. 761-777, 2014.
87. M. J. Alvarez-Figueroa and J. Blanco-Méndez, "Transdermal delivery of methotrexate: iontophoretic delivery fromhydrogels and passive delivery from microemulsions", International Journal of Pharmaceutics, vol. 215, no. 1-2, pp. 57-65, 2001.
88. G. Lu and H. W. Jun, "Diffusion studies of methotrexate in Carbopol and Poloxamer gels", International Journal of Pharmaceutics, vol. 160, no. 1, pp. 1-9, 1998.
89. F. C. Carvalho, G. Calixto, I. N. Hatakeyama, G. M. Luz, M. P. D. Gremião, and M. Chorilli, "Rheological, mechanical, and bioadhesive behavior of hydrogels to optimize skin delivery systems", Drug Development and Industrial Pharmacy, vol. 39, no. 11, pp. 1750-1757, 2013.
90. G. Calixto, A. C. Yoshii, H. Rocha E Silva, B. S. F. Cury, and M. Chorilli, "Polyacrylic acid polymers hydrogels intended to topical drug delivery: preparation and characterization", Pharmaceutical Development and Technology, 2014.
91. M. Redpath, C. M. G. Marques, C. Dibden, A. Waddon, R. Lalla, and S. MacNeil, "Ibuprofen and hydrogel-released ibuprofen in the reduction of inflammation-induced migration in melanoma cells", British Journal of Dermatology, vol. 161, no. 1, pp. 25-33, 2009.
92. M. J. Moura, M. H. Gil, and M. M. Figueiredo, "Delivery of cisplatin fromthermosensitive co-cross-linked chitosan hydrogels", European Polymer Journal, vol. 49, no. 9, pp. 2504-2510, 2013.
93. M. R. Bernsen, J.-W. Tang, L. A. Everse, J. W. Koten, and W. Den Otter, "Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration", Cancer Treatment Reviews, vol. 25, no. 2, pp. 73-82, 1999.
94. G. W. Bos, J. J. L. Jacobs, J. W. Koten et al., "In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy", European Journal of Pharmaceutical Sciences, vol. 21, no. 4, pp. 561-567, 2004.
95. T. Takei, K. Sugihara, M. Yoshida, and K. Kawakami, "Injectable and biodegradable sugar beet pectin/gelatin hydrogels for biomedical applications", Journal of Biomaterials Science, Polymer Edition, vol. 24, no. 11, pp. 1333-1342, 2013.
96. E. Ruel-Gariépy, M. Shive, A. Bichara et al., "A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel", European Journal of Pharmaceutics and Biopharmaceutics, vol. 57, no. 1, pp. 53-63, 2004.
97. W. S. Shim, J.-H. Kim, K. Kim et al., "pH- and temperaturesensitive, injectable, biodegradable block copolymer hydrogels as carriers for paclitaxel", International Journal of Pharmaceutics, vol. 331, no. 1, pp. 11-18, 2007.
98. C. C. Beh, R. Mammucari, and N. R. Foster, "Lipids-based drug carrier systems by dense gas technology: a review", Chemical Engineering Journal, vol. 188, pp. 1-14, 2012.
99. E. Fahy, S. Subramaniam, H. A. Brown et al., "Acomprehensive classification system for lipids", Journal of Lipid Research, vol. 46, no. 5, pp. 839-861, 2005.
100. D.-G. Yu, C. Branford-White, G. R. Williams et al., "Self-assembled liposomes from amphiphilic electrospun nanofibers", Soft Matter, vol. 7, no. 18, pp. 8239-8247, 2011.
101. S. Zhang, H.-J. Sun, A. D. Hughes et al., "'single-single' amphiphilic janus dendrimers self-assemble into uniform dendrimersomes with predictable size", ACS Nano, vol. 8, no. 2, pp. 1554-1565, 2014.
102. J. Muñoz and M. C. Alfaro, "Rheological and phase behaviour of amphiphilic lipids", Grasas y Aceites, vol. 51, no. 1-2, pp. 6-25, 2000.
103. M. Y. Vagin, E. V. Malyh, N. I. Larionova, and A. A. Karyakin, "Spontaneous and facilitated micelles formation at liquid/liquid interface: towards amperometric detection of redox inactive proteins", Electrochemistry Communications, vol. 5, no. 4, pp. 329-333, 2003.
104. M. C. Woodle and D. Papahadjopoulos, "Liposome preparation and size characterization", Methods in Enzymology, vol. 171, pp. 193-217, 1989.
105. W. R. Hargreaves, "Liposomes from ionic, single-chain amphiphiles", Biochemistry, vol. 17, no. 18, pp. 3759-3767, 1978.
106. F. Frézard, D. A. Schettini, O. G. Rocha, and C. Demicheli, "Lipossomas: propriedades físico-químicas e farmacológicas, aplicações na quimioterapia à base de antimônio", Química Nova, vol. 28, no. 3, pp. 511-518, 2005.
107. V. P. Torchilin, "Recent advances with liposomes as pharmaceutical carriers", Nature Reviews Drug Discovery, vol. 4, no. 2, pp. 145-160, 2005.
108. L. C. G. Machado, S. Anne, and M. L. W. Klüppel, "Liposomes applied in pharmacology: a review", Estudos de Biologia, vol. 29, no. 67, pp. 215-224, 2007.
109. A. N. Jatariu, M. Popa, and C. A. Peptu, "Different particulate systems-bypass the biological barriers", Journal of Drug Targeting, vol. 18, no. 4, pp. 243-253, 2010.
110. N. Berger, A. Sachse, J. Bender, R. Schubert, and M. Brandl, "Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics", International Journal of Pharmaceutics, vol. 223, no. 1-2, pp. 55-68, 2001.
111. M. M. Lapinski, A. Castro-Forero, A. J. Greiner, R. Y. Ofoli, and G. J. Blanchard, "Comparison of liposomes formed by sonication and extrusion: rotational and translational diffusion of an embedded chromophore", Langmuir, vol. 23, no. 23, pp. 11677-11683, 2007.
112. F. Olson, C. A. Hunt, F. C. Szoka, W. J. Vail, and D. Papahadjopoulos, "Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes", BBA-Biomembranes, vol. 557, no. 1, pp. 9-23, 1979.
113. E. Feitosa, P. C. A. Barreleiro, and G. Olofsson, "Phase transition in dioctadecyldimethylammonium bromide and chloride vesicles prepared by different methods", Chemistry and Physics of Lipids, vol. 105, no. 2, pp. 201-213, 2000.
114. D. G. Hunter and B. J. Frisken, "Effect of extrusion pressure and lipid properties on the size and polydispersity of lipid vesicles", Biophysical Journal, vol. 74, no. 6, pp. 2996-3002, 1998.
115. G. Maulucci, M. De Spirito, G. Arcovito, F. Boffi, A. C. Castellano, and G. Briganti, "Particle distribution in DMPC vesicles solutions undergoing different sonication times", Biophysical Journal, vol. 88, no. 5, pp. 3545-3550, 2005.
116. M. Owais and C. M. Gupta, "Targeted drug delivery to macrophages in parasitic infections", Current Drug Delivery, vol. 2, no. 4, pp. 311-318, 2005.
117. R. A. Schwendener, "Liposomes in biology and medicine", Advances in Experimental Medicine and Biology, vol. 620, pp. 117-128, 2007.
118. S. Bhowmick, R. Ravindran, and N. Ali, "Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarizedTh1 response", Vaccine, vol. 25, no. 35, pp. 6544-6556, 2007.
119. S. E. Treiger Borborema, R. A. Schwendener, J. A. Osso Junior, H. F. De Andrade Junior, and N. Do Nascimento, "Uptake and antileishmanial activity of meglumine antimoniatecontaining liposomes in Leishmania (Leishmania) majorinfected macrophages", International Journal of Antimicrobial Agents, vol. 38, no. 4, pp. 341-347, 2011.
120. P. Wolf, H. Maier, R. R. Müllegger et al., "Topical treatment with liposomes containing T4 endonuclease V protects human skin in vivo from ultraviolet-induced upregulation of interleukin-10 and tumor necrosis factor-α", Journal of Investigative Dermatology, vol. 114, no. 1, pp. 149-156, 2000.
121. D. Yarosh, J. Klein, A. O'Connor, J. Hawk, E. Rafal, and P. Wolf, "Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study", The Lancet, vol. 357, no. 9260, pp. 926-929, 2001.
122. M. B. Pierre, A. C. Tedesco, J. M. Marchetti, and M. V. Bentley, "Stratum corneum lipids liposomes for the topical delivery of 5-aminolevulinic acid in photodynamic therapy of skin cancer: preparation and in vitro permeation study", BMC Dermatology, vol. 1, no. 1, p. 5, 2001.
123. Y. Chen, Q. Wu, Z. Zhang, L. Yuan, X. Liu, and L. Zhou, "Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics", Molecules, vol. 17, no. 5, pp. 5972-5987, 2012.
124. M. Nobayashi, M. Mizuno, T. Kageshita, K. Matsumoto, T. Saida, and J. Yoshida, "Repeated cationic multilamellar liposome-mediated gene transfer enhanced transduction efficiency against murine melanoma cell lines", Journal of Dermatological Science, vol. 29, no. 3, pp. 206-213, 2002.
125. D. Liu, H. Hu, Z. Lin et al., "Quercetin deformable liposome: preparation and efficacy against ultraviolet B induced skin damages in vitro and in vivo", Journal of Photochemistry and Photobiology B: Biology, vol. 127, pp. 8-17, 2013.
126. E. M. M. Del Valle, "Cyclodextrins and their uses: a review", Process Biochemistry, vol. 39, no. 9, pp. 1033-1046, 2004.
127. M. Singh, R. Sharma, and U. C. Banerjee, "Biotechnological applications of cyclodextrins", Biotechnology Advances, vol. 20, no. 5-6, pp. 341-359, 2002.
128. A. L. Laza-Knoerr, R. Gref, and P. Couvreur, "Cyclodextrins for drug delivery", Journal of Drug Targeting, vol. 18, no. 9, pp. 645-656, 2010.
129. A. Biwer, G. Antranikian, and E. Heinzle, "Enzymatic production of cyclodextrins", Applied Microbiology and Biotechnology, vol. 59, no. 6, pp. 609-617, 2002.
130. T. Loftsson and D. Duchêne, "Cyclodextrins and their pharmaceutical applications", International Journal of Pharmaceutics, vol. 329, no. 1-2, pp. 1-11, 2007.
131. T. Loftsson and M. E. Brewster, "Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization", Journal of Pharmaceutical Sciences, vol. 85, no. 10, pp. 1017-1025, 1996.
132. T. Loftsson, M. Másson, and M. E. Brewster, "Self-association of cyclodextrins and cyclodextrin complexes", Journal of Pharmaceutical Sciences, vol. 93, no. 5, pp. 1091-1099, 2004.
133. J. Zhang and P. X. Ma, "Host-guest interactions mediated nanoassemblies using cyclodextrin-containing hydrophilic polymers and their biomedical applications", Nano Today, vol. 5, no. 4, pp. 337-350, 2010.
134. K. Uekama, "Design and evaluation of cyclodextrin-based drug formulation", Chemical and Pharmaceutical Bulletin, vol. 52, no. 8, pp. 900-915, 2004.
135. B. Gidwani and A. Vyas, "Synthesis, characterization and application of epichlorohydrin-β-cyclodextrin polymer", Colloids and Surfaces B: Biointerfaces, vol. 114, pp. 130-137, 2014.
136. N. C. Bellocq, S. H. Pun, G. S. Jensen, and M. E. Davis, "Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery", Bioconjugate Chemistry, vol. 14, no. 6, pp. 1122-1132, 2003.
137. S. Hu-Lieskovan, J. D. Heidel, D. W. Bartlett, M. E. Davis, and T. J. Triche, "Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma", Cancer Research, vol. 65, no. 19, pp. 8984-8992, 2005.
138. S. H. Pun, F. Tack, N. C. Bellocq et al., "Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles", Cancer Biology and Therapy, vol. 3, no. 7, pp. 641-650, 2004.
139. D. Michel, J. M. Chitanda, R. Balogh et al., "Design and evaluation of cyclodextrin-based delivery systems to incorporate poorly soluble curcumin analogs for the treatment of melanoma", European Journal of Pharmaceutics and Biopharmaceutics, vol. 81, no. 3, pp. 548-556, 2012.
140. S. Ganta, H. Devalapally, A. Shahiwala, and M. Amiji, "Areview of stimuli-responsive nanocarriers for drug and gene delivery", Journal of Controlled Release, vol. 126, no. 3, pp. 187-204, 2008.
141. I. F. Tannock and D. Rotin, "Acid pH in tumors and its potential for therapeutic exploitation", Cancer Research, vol. 49, no. 16, pp. 4373-4384, 1989.
142. Y. Liu, W. Wang, J. Yang, C. Zhou, and J. Sun, "pH-sensitive polymeric micelles triggered drug release for extracellular and intracellular drug targeting delivery", Asian Journal of Pharmaceutical Sciences, vol. 8, no. 3, pp. 159-167, 2013.
143. Z. Zhang, J. Ding, X. Chen et al., "Intracellular pH-sensitive supramolecular amphiphiles based on host-guest recognition between benzimidazole and β-cyclodextrin as potential drug delivery vehicles", Polymer Chemistry, vol. 4, no. 11, pp. 3265-3271, 2013.
144. H. He, S. Chen, J. Zhou et al., "Cyclodextrin-derived pHresponsive nanoparticles for delivery of paclitaxel", Biomaterials, vol. 34, no. 21, pp. 5344-5358, 2013.
145. F. Huang and H. W. Gibson, "Polypseudorotaxanes and polyrotaxanes", Progress in Polymer Science, vol. 30, no. 10, pp. 982-1018, 2005.
146. J. Chang, Y. Li, G. Wang, B. He, and Z. Gu, "Fabrication of novel coumarin derivative functionalized polypseudorotaxane micelles for drug delivery", Nanoscale, vol. 5, no. 2, pp. 813-820, 2013.
147. Z.-H. Chen and E. Niki, "4-Hydroxynonenal (4-HNE) has been widely accepted as an inducer of oxidative stress. Is this the whole truthabout it or can4-HNEalsoexert protective effects?" IUBMB Life, vol. 58, no. 5-6, pp. 372-373, 2006.
148. W. Siems and T. Grune, "Intracellular metabolism of 4-hydroxynonenal", Molecular Aspects of Medicine, vol. 24, no. 4-5, pp. 167-175, 2003.
149. S. Pizzimenti, E. Ciamporcero, P. Pettazzoni et al., "The inclusion complex of 4-hydroxynonenal with a polymeric derivative of β-cyclodextrin enhances the antitumoral efficacy of the aldehyde in several tumor cell lines and in a three-dimensional human melanoma model", Free Radical Biology and Medicine, vol. 65, pp. 765-777, 2013.
150. S. K. Rodal, G. Skretting, Ø. Garred, F. Vilhardt, B. Van Deurs, and K. Sandvig, "Extraction of cholesterol with methyl-β-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles", Molecular Biology of the Cell, vol. 10, no. 4, pp. 961-974, 1999.
151. I. S. Babina, S. Donatello, I. R. Nabi, and A. M. Hopkins, "Lipid rafts as master regulators of breast cancer cell function", in Breast Cancer-Carcinogenesis, Cell Growth and Signalling Pathways, M. Gunduz and E. Gunduz, Eds., chapter 19, InTech, 2011.
152. T. Murai, Y. Maruyama, K. Mio, H. Nishiyama, M. Suga, and C. Sato, "Low cholesterol triggers membrane microdomaindependent CD44 shedding and suppresses tumor cell migration", Journal of Biological Chemistry, vol. 286, no. 3, pp. 1999-2007, 2011.
153. P. Keller and K. Simons, "Cholesterol is required for surface transport of influenza virus hemagglutinin", Journal of Cell Biology, vol. 140, no. 6, pp. 1357-1367, 1998.
154. R. Onodera, K. Motoyama, A. Okamatsu et al., "Involvement of cholesterol depletion from lipid rafts in apoptosis induced by methyl-β-cyclodextrin", International Journal of Pharmaceutics, vol. 452, no. 1-2, pp. 116-123, 2013.
155. A. Mazzaglia, M. L. Bondì, A. Scala et al., "Supramolecular assemblies based on complexes of nonionic amphiphilic cyclodextrins and a meso-tetra (4-sulfonatophenyl) porphine tributyltin (IV) derivative: potential nanotherapeutics against melanoma", Biomacromolecules, vol. 14, no. 11, pp. 3820-3829, 2013.
156. G. S. Kienle and H. Kiene, "Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts", European Journal of Medical Research, vol. 12, no. 3, pp. 103-119, 2007.
157. E. Ernst, "The role of complementary and alternative medicine in cancer", The Lancet Oncology, vol. 1, no. 3, pp. 176-180, 2000.
158. C. M. Strüh, S. Jäger, A. Kersten, C. M. Schempp, A. Scheffler, and S. F. Martin, "Triterpenoids amplify anti-tumoral effects of mistletoe extracts on murine B16.f10 melanoma in vivo", PLoS ONE, vol. 8, no. 4, Article ID e62168, 2013.
159. R. H. Cichewicz and S. A. Kouzi, "Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection", Medicinal Research Reviews, vol. 24, no. 1, pp. 90-114, 2004.
160. C. Şoica, C. Dehelean, C. Danciu et al., "Betulin complex in γ-cyclodextrin derivatives: properties and antineoplasic activities in in vitro and in vivo tumor models", International Journal of Molecular Sciences, vol. 13, no. 11, pp. 14992-15011, 2012.
161. C. Nicholas and G. B. Lesinski, "Immunomodulatory cytokines as therapeutic agents for melanoma", Immunotherapy, vol. 3, no. 5, pp. 673-690, 2011.
162. R. A. Flavell, S. Sanjabi, S. H. Wrzesinski, and P. Licona-Limón, "The polarization of immune cells in the tumour environment by TGFβ", Nature Reviews Immunology, vol. 10, no. 8, pp. 554-567, 2010.
163. J. Park, S. H. Wrzesinski, E. Stern et al., "Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy", Nature Materials, vol. 11, no. 10, pp. 895-905, 2012.
164. S. B. Brown, E. A. Brown, and I. Walker, "The present and future role of photodynamic therapy in cancer treatment", The Lancet Oncology, vol. 5, no. 8, pp. 497-508, 2004.
165. H. Kolarova, J. Macecek, P. Nevrelova et al., "Photodynamic therapy with zinc-tetra (p-sulfophenyl) porphyrin bound to cyclodextrin induces single strand breaks of cellular DNA in G361 melanoma cells", Toxicology in Vitro, vol. 19, no. 7, pp. 971-974, 2005.
166. S. S. Guterres, M. P. Alves, and A. R. Pohlmann, "Polymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applications", Drug Target Insights, vol. 2, pp. 147-157, 2007.
167. V. Mohanraj and Y. Chen, "Nanoparticles-a review", Tropical Journal of Pharmaceutical Research, vol. 5, no. 1, pp. 561-573, 2006.
168. H. Bhargava, A. Narurkar, and L. Lieb, "Using microemulsions for drug delivery", Pharmaceutical Technology, vol. 11, no. 3, pp. 46-54, 1987.
169. T. P. Formariz, M. C. Urban, A. A. Silva Júnior, M. P. Gremião, and A. G. Oliveira, "Microemulsões e fases líquidas cristalinas como sistemas de liberação de fármacos", Revista Brasileira de Ciências Farmacêuticas, vol. 41, no. 3, pp. 301-313, 2005.
170. M. Chorilli, P. S. Prestes, R. B. Rigon, G. R. Leonardi, L. A. Chiavacci, and M. V. Scarpa, "Desenvolvimento de sistemas líquido-cristalinos empregando silicone fluido de co-polímero glicol e poliéter funcional siloxano", Química Nova, vol. 32, no. 4, pp. 1036-1040, 2009.
171. C. C. Mueller-Goymann and S. G. Frank, "Interaction of lidocaine and lidocaine-HCl with the liquid crystal structure of topical preparations", International Journal of Pharmaceutics, vol. 29, no. 2-3, pp. 147-159, 1986.
172. O. Lehmann, Flüssige Kristalle, Wilhelm Engelmann, Leipzig, Germany, 1904.
173. M. Ferrari, "Obtenção e aplicação de emulsões múltiplas contendo óleo de and iroba e copaíba", in Faculdade de Ciências Farmacêuticas de Ribeirão Preto, p. 147, Sao Paulo University, Ribeirão Preto, Brazil, 1998.
174. M. Urban, "Desenvolvimento de sistemas de liberação micro e nanoestruturados para administração cutânea do acetato de dexametasona", in Drugs and Medicines, p. 136, São Paulo State University, Araraquara, Brazil, 2004.
175. L. Bitan-Cherbakovsky, A. Aserin, and N. Garti, "Structural characterization of lyotropic liquid crystals containing a dendrimer for solubilization and release of gallic acid", Colloids and Surfaces B, vol. 112, pp. 87-95, 2013.
176. M. Gosenca, M. Bešter-Rogač, and M. Gašperlin, "Lecithin based lamellar liquid crystals as a physiologically acceptable dermal delivery system for ascorbyl palmitate", European Journal of Pharmaceutical Sciences, vol. 50, no. 1, pp. 114-122, 2013.
177. D. Bei, J. Marszalek, and B.-B. C. Youan, "Formulation of dacarbazine-loaded cubosomes-part I: influence of formulation variables", AAPS PharmSciTech, vol. 10, no. 3, pp. 1032-1039, 2009.
178. D. Bei, T. Zhang, J. B. Murowchick, and B.-B. C. Youan, "Formulation of dacarbazine-loaded cubosomes. Part III. physicochemical characterization", AAPS PharmSciTech, vol. 11, no. 3, pp. 1243-1249, 2010.
179. X. Gong, M. J. Moghaddam, S. M. Sagnella et al., "Lyotropic liquid crystalline self-assemblymaterial behavior and nanoparticulate dispersions of a phytanyl pro-drug analogue of capecitabine-a chemotherapy agent", ACS AppliedMaterials & Interfaces, vol. 3, no. 5, pp. 1552-1561, 2011.
180. K. L. Von Eckardstein, S. Patt, C. Kratzel, J. C. W. Kiwit, and R. Reszka, "Local chemotherapy of F98 rat glioblastoma with paclitaxel and carboplatin embedded in liquid crystalline cubic phases", Journal of Neuro-Oncology, vol. 72, no. 3, pp. 209-215, 2005.
181. K. L. Von Eckardstein, R. Reszka, and J. C. Kiwit, "Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma-clinical observations", Journal of Neuro-Oncology, vol. 74, no. 3, pp. 305-309, 2005.
182. S. B. Rizwan, Y.-D. Dong, B. J. Boyd, T. Rades, and S. Hook, "Characterisation of bicontinuous cubic liquid crystalline systems of phytantriol and water using cryo field emission scanning electron microscopy (cryo FESEM)", Micron, vol. 38, no. 5, pp. 478-485, 2007.
183. N. Zeng, Q. Hu, Z. Liu et al., "Preparation and characterization of paclitaxel-loadedDSPE-PEG-liquid crystalline nanoparticles (LCNPs) for improved bioavailability", International Journal of Pharmaceutics, vol. 424, no. 1-2, pp. 58-66, 2012.
184. D. Bei, J. Marszalek, and B.-B. C. Youan, "Formulation of dacarbazine-loaded cubosomes-part II: influence of process parameters", AAPS PharmSciTech, vol. 10, no. 3, pp. 1040-1047, 2009.
185. L. Mu and S. S. Feng, "A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS", Journal of Controlled Release, vol. 86, no. 1, pp. 33-48, 2003.
186. A. Pampel, D. Michel, and R. Reszka, "Pulsed field gradient MAS-NMR studies of the mobility of carboplatin in cubic liquid-crystalline phases", Chemical Physics Letters, vol. 357, no. 1-2, pp. 131-136, 2002.
187. A. Dowling, R. Clift, N. Grobert et al., "Nanoscience and nanotechnologies: opportunities and uncertainties", The Royal Society & The Royal Academy of Engineering Report, Royal Academy of Engineering, London, UK, 2004.
188. P. K. Jain, K. S. Lee, I. H. El-Sayed, and M. A. El-Sayed, "Calculated absorption and scattering properties of gold nanoparticles of different size, shape, and composition: applications in biological imaging and biomedicine", The Journal of Physical Chemistry B, vol. 110, no. 14, pp. 7238-7248, 2006.
189. K. A. Howard, U. L. Rahbek, X. Liu et al., "RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system", MolecularTherapy, vol. 14, no. 4, pp. 476-484, 2006.
190. P. L. Apopa, Y. Qian, R. Shao et al., "Iron oxide nanoparticles induce human microvascular endothelial cell permeability through reactive oxygen species production and microtubule remodeling", Particle and Fibre Toxicology, vol. 6, no. 1, Article 1, 2009.
191. M. Auffan, J. Rose, J.-Y. Bottero, G. V. Lowry, J.-P. Jolivet, and M. R. Wiesner, "Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective", Nature Nanotechnology, vol. 4, no. 10, pp. 634-641, 2009.
192. Food and Drug Administration (FDA), Guidance for Industry: Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients That are Color Additives, Food and Drug Administration (FDA), Silver Spring, Md, USA, 2012.
193. R. Müller and J. Lucks, "Arzneistoffträger aus festen lipidteilchen, feste lipidnanosphären (sln)", European Patent, 1996.
194. R. H. Müller, R. D. Petersen, A. Hommoss, and J. Pardeike, "Nanostructured lipid carriers (NLC) in cosmetic dermal products", Advanced Drug Delivery Reviews, vol. 59, no. 6, pp. 522-530, 2007.
195. W. Mehnert and K. Mäder, "Solid lipid nanoparticles: production, characterization and applications", Advanced Drug Delivery Reviews, vol. 47, no. 2-3, pp. 165-196, 2001.
196. E. B. Souto, A. J. Almeida, and R. H. Müller, "Lipid nanoparticles (SLN, NLC) for cutaneous drug delivery: structure, protection and skin effects", Journal of Biomedical Nanotechnology, vol. 3, no. 4, pp. 317-331, 2007.
197. Y.-C. Kuo and C.-C. Wang, "Cationic solid lipid nanoparticles with primary and quaternary amines for release of saquinavir and biocompatibility with endothelia", Colloids and Surfaces B: Biointerfaces, vol. 101, pp. 101-105, 2013.
198. Y.-C. Kuo and C.-T. Liang, "Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells", Colloids and Surfaces B: Biointerfaces, vol. 85, no. 2, pp. 131-137, 2011.
199. F. Canfarotta, M. J. Whitcombe, and S. A. Piletsky, "Polymeric nanoparticles for optical sensing", Biotechnology Advances, vol. 31, no. 8, pp. 1585-1599, 2013.
200. C.-M. J. Hu and L. Zhang, "Nanoparticle-based combination therapy toward overcoming drug resistance in cancer", Biochemical Pharmacology, vol. 83, no. 8, pp. 1104-1111, 2012.
201. H. Fessi, F. Piusieux, J. P. Devissaguet, N. Ammoury, and S. Benita, "Nanocapsule formation by interfacial polymer deposition following solvent displacement", International Journal of Pharmaceutics, vol. 55, no. 1, pp. R1-R4, 1989.
202. N. Al Khouri Fallouh, L. Roblot-Treupel, and H. Fessi, "Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules", International Journal of Pharmaceutics, vol. 28, no. 2-3, pp. 125-132, 1986.
203. B. Magenheim and S. Benita, "Nanoparticle characterization: a comprehensive physicochemical approach", STP Pharma Sciences, vol. 1, no. 4, pp. 221-241, 1991.
204. K. S. Soppimath, T. M. Aminabhavi, A. R. Kulkarni, and W. E. Rudzinski, "Biodegradable polymeric nanoparticles as drug delivery devices", Journal of Controlled Release, vol. 70, no. 1-2, pp. 1-20, 2001.
205. G. Orive, E. Anitua, J. L. Pedraz, and D. F. Emerich, "Biomaterials for promoting brain protection, repair and regeneration", Nature Reviews Neuroscience, vol. 10, no. 9, pp. 682-692, 2009.
206. K. Letchford and H. Burt, "A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes", European Journal of Pharmaceutics and Biopharmaceutics, vol. 65, no. 3, pp. 259-269, 2007.
207. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation", Cell, vol. 144, no. 5, pp. 646-674, 2011.
208. A. Jain, K. Jain, P. Kesharwani, and N. K. Jain, "Low density lipoproteins mediated nanoplatforms for cancer targeting", Journal of Nanoparticle Research, vol. 15, no. 9, Article 1888, 38 pages, 2013.
209. H. Hillaireau and P. Couvreur, "Nanocarriers' entry into the cell: relevance to drug delivery", Cellular and Molecular Life Sciences, vol. 66, no. 17, pp. 2873-2896, 2009.
210. J. H. Sakamoto, A. L. Van De Ven, B. Godin et al., "Enabling individualized therapy through nanotechnology", Pharmacological Research, vol. 62, no. 2, pp. 57-89, 2010.
211. Y.-C. Kuo and H.-H. Chen, "Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells", Journal of Drug Targeting, vol. 18, no. 6, pp. 447-456, 2010.
212. D. E. Owens III and N. A. Peppas, "Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles", International Journal of Pharmaceutics, vol. 307, no. 1, pp. 93-102, 2006.
213. A. Gabizon and F. Martin, "Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours", Drugs, vol. 54, no. 4, pp. 15-21, 1997.
214. T. Ameller, V. Marsaud, P. Legrand, R. Gref, G. Barratt, and J.-M. Renoir, "Polyester-poly (ethylene glycol) nanoparticles loaded with the pure antiestrogen RU 58668: physicochemical and opsonization properties", Pharmaceutical Research, vol. 20, no. 7, pp. 1063-1070, 2003.
215. K. Na, E. S. Lee, and Y. H. Bae, "Adriamycin loaded pullulan acetate/sulfonamide conjugate nanoparticles responding to tumor pH: pH-dependent cell interaction, internalization and cytotoxicity in vitro", Journal of Controlled Release, vol. 87, no. 1-3, pp. 3-13, 2003.
216. F. Sonvico, S. Mornet, S. Vasseur et al., "Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments", Bioconjugate Chemistry, vol. 16, no. 5, pp. 1181-1188, 2005.
217. H. L. Wong, R. Bendayan, A. M. Rauth, H. Y. Xue, K. Babakhanian, and X. Y. Wu, "A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system", Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 3, pp. 1372-1381, 2006.
218. E. Ristorcelli, E. Beraud, P. Verrando et al., "Human tumor nanoparticles induce apoptosis of pancreatic cancer cells", The FASEB Journal, vol. 22, no. 9, pp. 3358-3369, 2008.
219. R. A. Parlo and P. S. Coleman, "Enhanced rate of citrate export from cholesterol-rich hepatoma mitochondria. The truncated Krebs cycle and other metabolic ramifications of mitochondrial membrane cholesterol", Journal of Biological Chemistry, vol. 259, no. 16, pp. 9997-10003, 1984.
220. H. L. Wong, R. Bendayan, A. M. Rauth, Y. Li, and X. Y. Wu, "Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles", Advanced Drug Delivery Reviews, vol. 59, no. 6, pp. 491-504, 2007.
221. Y. Noguchi, J. Wu, R. Duncan et al., "Early phase tumor accumulation of Macromolecules: a great difference in clearance rate between tumor and normal tissues", Japanese Journal of Cancer Research, vol. 89, no. 3, pp. 307-314, 1998.
222. A. K. Iyer, G. Khaled, J. Fang, and H. Maeda, "Exploiting the enhanced permeability and retention effect for tumor targeting", Drug Discovery Today, vol. 11, no. 17-18, pp. 812-818, 2006.
223. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review", Journal of Controlled Release, vol. 65, no. 1-2, pp. 271-284, 2000.
224. Z. Xu, L. Chen, W. Gu et al., "The performance of docetaxelloaded solid lipid nanoparticles targeted to hepatocellular carcinoma", Biomaterials, vol. 30, no. 2, pp. 226-232, 2009.
225. J. Dausend, A. Musyanovych, M. Dass et al., "Uptake mechanism of oppositely charged fluorescent nanoparticles in HeLa cells", Macromolecular Bioscience, vol. 8, no. 12, pp. 1135-1143, 2008.
226. E. Chang, N. Thekkek, W. W. Yu, V. L. Colvin, and R. Drezek, "Evaluation of quantum dot cytotoxicity based on intracellular uptake", Small, vol. 2, no. 12, pp. 1412-1417, 2006.
227. T. Xia, M. Kovochich, M. Liong, J. I. Zink, and A. E. Nel, "Cationic polystyrene nanosphere toxicity depends on cellspecific endocytic and mitochondrial injury pathways", ACS Nano, vol. 2, no. 1, pp. 85-96, 2008.
228. L. Guo, Y. Peng, J. Yao, L. Sui, A. Gu, and J. Wang, "Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice", Cancer Biotherapy and Radiopharmaceuticals, vol. 25, no. 4, pp. 471-477, 2010.
229. K. Teskač and J. Kristl, "The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol", International Journal of Pharmaceutics, vol. 390, no. 1, pp. 61-69, 2010.
230. Z.-R. Huang, S.-C. Hua, Y.-L. Yang, and J.-Y. Fang, "Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion", Acta Pharmacologica Sinica, vol. 29, no. 9, pp. 1094-1102, 2008.
231. D. Liu, Z. Liu, L. Wang, C. Zhang, and N. Zhang, "Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel", Colloids and Surfaces B: Biointerfaces, vol. 85, no. 2, pp. 262-269, 2011.
232. S.-H. Hsu, C.-J. Wen, S. A. Al-Suwayeh, Y.-J. Huang, and J.-Y. Fang, "Formulation design and evaluation of quantum dotloaded nanostructured lipid carriers for integrating bioimaging and anticancer therapy", Nanomedicine, vol. 8, no. 8, pp. 1253-1269, 2013.
233. K. S. Ho and M. S. Shoichet, "Design considerations of polymeric nanoparticle micelles for chemotherapeutic delivery", CurrentOpinion in Chemical Engineering, vol. 2, no. 1, pp. 53-59, 2013.
234. H. Yao, S. S. Ng, L.-F. Huo et al., "Effective melanoma immunotherapy with interleukin-2 delivered by a novel polymeric nanoparticle", Molecular CancerTherapeutics, vol. 10, no. 6, pp. 1082-1092, 2011.
235. A. R. Khuda-Bukhsh, S. S. Bhattacharyya, S. Paul, and N. Boujedaini, "Polymeric nanoparticle encapsulation of a naturally occurring plant scopoletin and its effects on human melanoma cell A375", Journal of Chinese Integrative Medicine, vol. 8, no. 9, pp. 853-862, 2010.
236. S. Das, J. Das, A. Samadder, A. Paul, and A. R. Khuda-Bukhsh, "Strategic formulation of apigenin-loaded PLGA nanoparticles for intracellular trafficking, DNAtargeting and improved therapeutic effects in skin melanoma in vitro", Toxicology Letters, vol. 223, no. 2, pp. 124-138, 2013.
237. D. Vieira, V. Kim, D. Petri, C. Menck, and A. Carmona-Ribeiro, "Polymer-based delivery vehicle for cisplatin", Nanotechnology, vol. 3, pp. 382-385, 2011.
238. V. Mailänder, M. R. Lorenz, V. Holzapfel et al., "Carboxylated superparamagnetic iron oxide particles label cells intracellularly without transfection agents", Molecular Imaging and Biology, vol. 10, no. 3, pp. 138-146, 2008.
239. A. Ades, J. P. Carvalho, S. R. Graziani et al., "Uptake of a cholesterol-rich emulsion by neoplastic ovarian tissues", Gynecologic Oncology, vol. 82, no. 1, pp. 84-87, 2001.
240. D. Gal, M. Ohashi, P. C. MacDonald, H. J. Buchsbaum, and E. R. Simpson, "Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms", American Journal of Obstetrics and Gynecology, vol. 139, no. 8, pp. 877-885, 1981.
241. M. J. Rudling, V. P. Collins, and C. O. Peterson, "Delivery of aclacinomycin A to human glioma cells in vitro by the lowdensity lipoprotein pathway", Cancer Research, vol. 43, no. 10, pp. 4600-4605, 1983.
242. M. Masquelier, S. Vitols, and C. Peterson, "Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drughumanlow-density lipoprotein complexes in mice", Cancer Research, vol. 46, no. 8, pp. 3842-3847, 1986.
243. B. Lundberg, "Preparation of drug low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway", Cancer Research, vol. 47, no. 15, pp. 4105-4108, 1987.
244. H. Jin, J. F. Lovell, J. Chen et al., "Cytosolic delivery of LDL nanoparticle cargo using photochemical internalization", Photochemical and Photobiological Sciences, vol. 10, no. 5, pp. 810-816, 2011.
245. R. R. Allison and K. Moghissi, "Oncologic photodynamic therapy: clinical strategies that modulate mechanisms of action", Photodiagnosis and Photodynamic Therapy, vol. 10, no. 4, pp. 331-341, 2013.
246. C. J. Field and P. D. Schley, "Evidence for potential mechanisms for the effect of conjugated linoleic acid on tumor metabolism and immune function: lessons from n-3 fatty acids", The American Journal of Clinical Nutrition, vol. 79, no. 6, pp. 1190S-1198S, 2004.
247. J. S. Falconer, J. A. Ross, K. C. H. Fearon, R. A. Hawkins, M. G. O'Riordain, and D. C. Carter, "Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines", British Journal of Cancer, vol. 69, no. 5, pp. 826-832, 1994.
248. S. Jaracz, J. Chen, L. V. Kuznetsova, and I. Ojima, "Recent advances in tumor-targeting anticancer drug conjugates", Bioorganic and Medicinal Chemistry, vol. 13, no. 17, pp. 5043-5054, 2005.
249. X.-Y. Yang, Y.-X. Li, M. Li, L. Zhang, L.-X. Feng, and N. Zhang, "Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer", Cancer Letters, vol. 334, no. 2, pp. 338-345, 2013.
250. K. Y. Choi, H. Chung, K. H. Min et al., "Self-assembled hyaluronic acid nanoparticles for active tumor targeting", Biomaterials, vol. 31, no. 1, pp. 106-114, 2010.
251. K. Y. Choi, K. H. Min, H. Y. Yoon et al., "PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo", Biomaterials, vol. 32, no. 7, pp. 1880-1889, 2011.
252. J. D. Byrne, T. Betancourt, and L. Brannon-Peppas, "Active targeting schemes for nanoparticle systems in cancer therapeutics", Advanced Drug Delivery Reviews, vol. 60, no. 15, pp. 1615-1626, 2008.
253. J. F. Kukowska-Latallo, K. A. Candido, Z. Cao et al., "Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer", Cancer Research, vol. 65, no. 12, pp. 5317-5324, 2005.
254. C. P. Leamon and J. A. Reddy, "Folate-targeted chemotherapy", Advanced Drug Delivery Reviews, vol. 56, no. 8, pp. 1127-1141, 2004.
255. Y. Malam, M. Loizidou, and A. M. Seifalian, "Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer", Trends in Pharmacological Sciences, vol. 30, no. 11, pp. 592-599, 2009.
256. D. Labarre, C. Vauthier, C. Chauvierre, B. Petri, R. Müller, and M. M. Chehimi, "Interactions of blood proteins with poly (isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush", Biomaterials, vol. 26, no. 24, pp. 5075-5084, 2005.
257. R.-L. Hong, C.-J. Huang, Y.-L. Tseng et al., "Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?" Clinical Cancer Research, vol. 5, no. 11, pp. 3645-3652, 1999.
258. Y. Sheng, C. Liu, Y. Yuan et al., "Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan", Biomaterials, vol. 30, no. 12, pp. 2340-2348, 2009.
259. S. Krasnici, A. Werner, M. E. Eichhorn et al., "Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels", International Journal of Cancer, vol. 105, no. 4, pp. 561-567, 2003.
260. R. Kunstfeld, G. Wickenhauser, U. Michaelis et al., "Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a 'humanized' SCID mouse model", Journal of Investigative Dermatology, vol. 120, no. 3, pp. 476-482, 2003.
261. S. Ran, A. Downes, and P. E. Thorpe, "Increased exposure of anionic phospholipids on the surface of tumor blood vessels", Cancer Research, vol. 62, no. 21, pp. 6132-6140, 2002.
262. A. S. Hoffman, "Hydrogels for biomedical applications", Advanced Drug Delivery Reviews, vol. 64, pp. 18-23, 2012.
263. T. P. Chelvi and R. Ralhan, "Designing of thermosensitive liposomes from natural lipids for multimodality cancer therapy", International Journal of Hyperthermia, vol. 11, no. 5, pp. 685-695, 1995.
264. S. Batzri and E. D. Korn, "Single bilayer liposomes prepared without sonication", Biochimica et Biophysica Acta-Biomembranes, vol. 298, no. 4, pp. 1015-1019, 1973.
265. J. J. Escobar-Chávez, "Nanocarriers for transdermal drug delivery", Skin, vol. 19, p. 22, 2012.
266. M. R. Mozafari, "Liposomes: an overview of manufacturing techniques", Cellular and Molecular Biology Letters, vol. 10, no. 4, pp. 711-719, 2005.
267. M. Malmsten, "Soft drug delivery systems", Soft Matter, vol. 2, no. 9, pp. 760-769, 2006.
268. R. A. Rajewski and V. J. Stella, "Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery", Journal of Pharmaceutical Sciences, vol. 85, no. 11, pp. 1142-1169, 1996.
269. A. F. Soares, R. D. A. Carvalho, and F. Veiga, "Oral administration of peptides and proteins: nanoparticles and cyclodextrins as biocompatible delivery systems", Nanomedicine, vol. 2, no. 2, pp. 183-202, 2007.
270. P. S. Prestes, M. Chorilli, L. A. Chiavacci, M. V. Scarpa, and G. R. Leonardi, "Physicochemical characterization and rheological behavior evaluation of the liquid crystalline mesophases developed with different silicones", Journal of Dispersion Science and Technology, vol. 31, no. 1, pp. 117-123, 2009.
271. M. Rückert and G. Otting, "Alignment of biological macromolecules in novel nonionic liquid crystalline media for NMR experiments", Journal of the American Chemical Society, vol. 122, no. 32, pp. 7793-7797, 2000.
272. E. B. Souto, P. Severino, M. H. A. Santana, and S. C. Pinho, "Solid lipid nanoparticles: classical methods of lab production", Quimica Nova, vol. 34, no. 10, pp. 1762-1769, 2011.
273. S. Shi, L. Han, L. Deng et al., "Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression", Journal of Controlled Release, vol. 194, pp. 228-237, 2014.
274. L. Mazzarino, L. F. C. Silva, J. C. Curta et al., "Curcuminloaded lipid and polymeric nanocapsules stabilized by nonionic surfactants: an in vitro and in vivo antitumor activity on B16-F10 melanoma and macrophage uptake comparative study", Journal of Biomedical Nanotechnology, vol. 7, no. 3, pp. 406-414, 2011.
275. L. Cai, X. Wang, W. Wang et al., "Peptide ligand and PEGmediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo", International Journal of Nanomedicine, vol. 7, pp. 4499-4510, 2012.
276. Y. Barenholz, "Doxil-The first FDA-approved nano-drug: lessons learned", Journal of Controlled Release, vol. 160, no. 2, pp. 117-134, 2012.
277. A. S. Yang and P. B. Chapman, "The history and future of chemotherapy for melanoma", Hematology/Oncology Clinics of North America, vol. 23, no. 3, pp. 583-597, 2009.
278. M. Ugurel, D. Schadendorf, W. Fink et al., "Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma", Onkologie, vol. 27, no. 6, pp. 540-544, 2004.
279. W.-J. Hwu, K. S. Panageas, J. H. Menell et al., "Phase II study of temozolomide plus pegylated interferon-α-2b for metastatic melanoma", Cancer, vol. 106, no. 11, pp. 2445-2451, 2006.
280. P. Decuzzi and M. Ferrari, "The receptor-mediated endocytosis of nonspherical particles", Biophysical Journal, vol. 94, no. 10, pp. 3790-3797, 2008.
281. H. K. Sajja, M. P. East, H. Mao, Y. A. Wang, S. Nie, and L. Yang, "Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect", Current Drug Discovery Technologies, vol. 6, no. 1, pp. 43-51, 2009.
282. D. Rosenblum and D. Peer, "Omics-based nanomedicine: the future of personalized oncology", Cancer Letters, vol. 352, no. 1, pp. 126-136, 2013